Spyre Therapeutics, Inc. Common Stock
SYRE
$76.44
+6.17%
Spyre Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing long-acting antibodies and antibody combinations for the treatment of inflammatory bowel disease (IBD) and rheumatic diseases. The company operates as a pre-revenue biotech disruptor, aiming to redefine the standard of care in the competitive IBD market with its pipeline targeting α4β7, TL1A, and IL-23. The current investor narrative is overwhelmingly driven by clinical and pipeline optimism, as evidenced by the stock's dramatic surge over the past year, with recent attention focused on a proposed public offering to fund pipeline development and significant institutional investment signaling strong confidence in its long-term prospects.…
SYRE
Spyre Therapeutics, Inc. Common Stock
$76.44
Related headlines
SYRE 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Spyre Therapeutics, Inc. Common Stock's 12-month outlook, with a consensus price target around $99.37 and implied upside of +30.0% versus the current price.
Average Target
$99.37
4 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
4
covering this stock
Price Range
$61 - $99
Analyst target range
Analyst coverage is limited, with only 4 analysts currently providing estimates, which is typical for a clinical-stage biotech and can lead to higher volatility and less efficient price discovery. The provided data includes only estimated EPS and revenue averages, lacking consensus price targets, recommendation distributions, or target ranges; therefore, the implied upside or downside cannot be calculated, and the strength of analyst conviction remains unclear due to this insufficient data.
Bulls vs Bears: SYRE Investment Factors
The bull case for SYRE is powerful but speculative, built entirely on clinical promise and momentum, evidenced by its 375% annual surge and strong institutional backing. The bear case is equally compelling, grounded in an extreme valuation for a company with no revenue, high cash burn, and parabolic technical overextension. Currently, the bear side holds stronger evidence from a risk/reward perspective, as the stock's price already reflects near-perfect execution. The single most important tension in the investment debate is the chasm between the market's sky-high expectations (priced in at a ~$11B valuation) and the binary, high-risk nature of clinical-stage biotech development. The resolution of this tension—through either clinical success or failure—will overwhelmingly determine the stock's ultimate direction.
Bullish
- Parabolic 1-Year Price Surge: The stock has risen 375.06% over the past year, dramatically outperforming the S&P 500's 27.04% gain. This extreme momentum reflects overwhelming market optimism for the company's pipeline targeting inflammatory bowel disease (IBD).
- Strong Institutional Confidence: A major fund recently invested $10.5 million, bringing its total stake to $78 million. This significant capital commitment from a sophisticated investor signals strong conviction in Spyre's long-term clinical and commercial prospects.
- Robust Balance Sheet & Liquidity: The company has a pristine balance sheet with zero debt-to-equity and a high current ratio of 13.25. This financial fortress provides ample runway to fund clinical development without the immediate pressure of debt servicing.
- Expected Reduction in Losses: The forward P/E of -25.89 is significantly less negative than the trailing P/E of -73.04. This gap implies analysts expect a meaningful reduction in net losses per share in the coming year, a key step towards future profitability.
Bearish
- Extreme Valuation & No Revenue: The stock trades at a market cap of ~$11.34 billion despite being a pre-revenue, clinical-stage company. With negative P/E, P/CF (-66.98), and EV/EBITDA (-53.69), the valuation discounts near-perfect clinical success, leaving no room for error.
- Parabolic Technical Overextension: At $78.48, the stock trades at 98.7% of its 52-week high ($79.54) after a 375% run. This extreme positioning near all-time highs signals severe overbought conditions and high susceptibility to a sharp, profit-driven correction, as seen in its -20.91% max drawdown.
- High Cash Burn & Dilution Risk: The negative price-to-cash-flow of -66.98 confirms the company is a significant cash consumer. The recently announced public offering, while funding the pipeline, introduces near-term dilution risk for existing shareholders.
- Extreme Volatility & Market Beta: With a beta of 3.13, SYRE is over 200% more volatile than the broader market. This extreme volatility makes the stock highly sensitive to sector rotations, biotech sentiment shifts, and macro headwinds, amplifying downside risk.
SYRE Technical Analysis
The stock is in a powerful, sustained uptrend, evidenced by a staggering 1-year price change of +375.06%. As of the latest close at $78.48, the stock is trading at approximately 98.7% of its 52-week high of $79.54, positioning it at the very top of its range, which signals extreme momentum but also raises significant overextension and profit-taking risks. Recent short-term momentum remains robust but shows signs of volatility; the 1-month price change is +10.52% and the 3-month change is +95.47%, indicating acceleration from the longer-term trend, though the path has been punctuated by sharp pullbacks like the -20.91% max drawdown. Key technical support is anchored near the 52-week low of $13.93, while immediate resistance is the 52-week high of $79.54; a decisive breakout above this level could signal a continuation of the parabolic move, while a failure could trigger a sharp correction. The stock's beta of 3.13 indicates it is over 200% more volatile than the broader market (SPY), which is critical for risk management as it implies outsized moves in both directions.
Beta
3.06
3.06x market volatility
Max Drawdown
-20.9%
Largest decline past year
52-Week Range
$14-$80
Price range past year
Annual Return
+345.5%
Cumulative gain past year
| Period | SYRE Return | S&P 500 |
|---|---|---|
| 1m | +1.9% | -0.1% |
| 3m | +84.2% | +9.0% |
| 6m | +122.5% | +7.0% |
| 1y | +345.5% | +22.9% |
| ytd | +150.0% | +8.1% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
SYRE Fundamental Analysis
As a clinical-stage biotech, Spyre Therapeutics currently generates no product revenue, with its financials reflecting a pure investment phase; the most recent quarterly revenue data is not available, but analyst estimates for the year average $121.0 million, which likely represents milestone or collaboration revenue rather than commercial sales. The company is deeply unprofitable, with a trailing EPS of -$0.01 and negative net margin, gross margin, and operating margin (all reported as 0% in the valuation data, indicating no commercial operations); the path to profitability is entirely dependent on successful clinical development and future commercialization, with losses expected to continue. The balance sheet appears strong from a liquidity standpoint with a high current ratio of 13.25 and zero debt-to-equity, but the company is a significant cash consumer, as indicated by a negative price-to-cash-flow ratio of -66.98, necessitating external financing like the recently announced public offering to fund its ambitious pipeline.
Quarterly Revenue
N/A
N/A
Revenue YoY Growth
N/A
YoY Comparison
Gross Margin
N/A
Latest Quarter
Free Cash Flow
N/A
Last 12 Months
Open an Account, get $2 TSLA now!
Valuation Analysis: Is SYRE Overvalued?
Given the company's negative net income and EBITDA, the primary valuation metric is the Price-to-Sales (PS) ratio; however, the provided PS ratio is 0, which is inconsistent with a positive market cap, suggesting a data error, so we must rely on alternative metrics like the negative trailing PE of -73.04 and forward PE of -25.89. Peer comparison is challenging due to missing industry average data, but the stock's market cap of approximately $11.34 billion for a pre-revenue company implies an extremely high valuation that discounts future success, with the gap between the trailing and forward PE (from -73x to -26x) suggesting analysts expect significant reductions in net losses per share in the coming year. Historical context is unavailable due to missing historical ratios data, but the stock's meteoric 1-year rise of +375% suggests the market has rapidly priced in highly optimistic expectations for its pipeline, leaving little room for clinical setbacks.
PE
-73.0x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-53.7x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks are severe and centered on the company's pre-revenue status. Spyre has no product revenue, negative EPS (-$0.01), and negative margins across the board. Its valuation metrics (P/E of -73, P/CF of -67) reflect a pure cash-burn operation. The company's strong liquidity (current ratio 13.25) is a necessity, not a luxury, as it funds an expensive clinical pipeline. The primary financial risk is dependence on continuous external financing, as evidenced by the recent public offering, which leads to shareholder dilution. Revenue concentration is 100% on future pipeline success, with no diversified income streams to cushion clinical setbacks.
Market & Competitive Risks are amplified by the stock's extreme valuation and volatility. Trading at ~98.7% of its 52-week high after a parabolic move, SYRE faces immense valuation compression risk if biotech sentiment sours or growth stock multiples contract. Its beta of 3.13 confirms it will experience outsized moves during market downturns. Competitively, the IBD space is crowded with large, well-funded incumbents. Any negative clinical data from Spyre or positive data from a competitor could swiftly erode its perceived market opportunity. The limited analyst coverage (only 4 analysts) exacerbates price discovery inefficiency and volatility.
Worst-Case Scenario involves a material clinical setback for its lead pipeline assets, such as a failed Phase 2 trial. This would shatter the narrative driving its $11.34 billion valuation, triggering massive institutional selling. Combined with a broader biotech sector downturn, this could catalyze a violent mean reversion. The realistic downside is severe, with the stock potentially retracing a significant portion of its 375% gain. A return to the 52-week low of $13.93 represents a potential loss of approximately -82% from the current price of $78.48. Even a less dramatic correction to the $30-$40 range, where it consolidated earlier in the year, would imply a -50% to -60% decline.